


PARTIAL SYNTHESIS OF AVERMECTIN B_{1a} AND IVERMECTIN FROM AVERMECTIN B_{2a}

H. Mrozik,* P. Eskola and M. H. Fisher

Merck Sharp & Dohme Research Laboratories, P. O. Box 2000, Rahway, New Jersey 07065

4'',5-Bis-O-(tert-butyldimethylsilyloxyacetyl)-23-O-(4-methylphenyloxythiocarbonyl)avermectin B_{2a} gave on pyrolysis and deprotection avermectin B_{1a}, while reduction with tri-n-butyltin hydride followed by deprotection afforded 22,23-dihydroavermectin B_{1a} (ivermectin).

The fermentation of *S. avermitilis* produces the structurally closely related avermectins B_{1a} (6) and B_{2a} (1) in substantial amounts.^{1,2} Avermectin B_{1a} (6) is superior in its anthelmintic activities³ and can be selectively reduced with Wilkinson's catalyst at the 22,23-double bond to the commercial anthelmintic ivermectin (9).⁴ Selective and regiospecific dehydration of the 23-hydroxy group of 1 to a 22,23-double bond is required for conversion of 1 into the desired 6. As the single hydrogen atom at the adjacent 24-position is *trans* to the axial 23-hydroxy group, a thermal *cis*-elimination should provide exclusively the 22,23-dehydro compound (6). Selective acylation of 1 with *tert*-butyldimethylsilyloxyacetyl-



- | | |
|--|---|
| 1 R _{4''} = R ₅ = H; R ₂₃ = OH | 6 R _{4''} = R ₅ = H; C ₂₂ -C ₂₃ = -CH=CH- |
| 2 R _{4''} = R ₅ = TBDMSOCH ₂ CO; R ₂₃ = OH | 7 R _{4''} = R ₅ = TBDMSOCH ₂ CO; R ₂₃ = H |
| 3 R _{4''} = R ₅ = TBDMSOCH ₂ CO; R ₂₃ = (4-CH ₃ C ₆ H ₄ O)C(S)O | 8 R _{4''} = R ₅ = HOCH ₂ CO; R ₂₃ = H |
| 4 R _{4''} = R ₅ = TBDMSOCH ₂ CO; C ₂₂ -C ₂₃ = -CH=CH- | 9 R _{4''} = R ₅ = H; R ₂₃ = H |
| 5 R _{4''} = R ₅ = HOCH ₂ CO; C ₂₂ -C ₂₃ = -CH=CH- | |

chloride⁵ (3 equivalents, ether, pyridine, 60 min, 0°) gave the 4'',5-diacyl derivative 2^{6,8} [48%, MS: 756, 429, 323, 433; NMR (CDCl₃) δ 5.59 (m, 2H, C₃H, C₅H), 4.75 (t, J = 9, C₄H), 4.34 and 4.28 (two s, 4H, 2x OCH₂CO), 3.35 (s, 3H, C₃H-OCH₃), 1.77 (s, 3H, C₄-CH₃), 0.92 (s, ~18H, 2x Si(CH₃)₃), 0.12 (s, ~12H, 2x Si(CH₃)₂)]. This leaves the remaining secondary 23-hydroxy group available for acylation with O-4-methylphenylchlorothioformate (3 equivalents, pyridine, 0°, then 8 h 18°) to give 3⁸ [44%, MS with elimination of HOC(S)OC₇H₇: 738, 429, 305, 433; NMR (CDCl₃) δ 7.21 and 6.99 (two d, J = 8, 4H, 1,4-disubst. C₆H₄); 5.39 (m, 1H, C₂₃H); 2.36 (s, 3H, arom. CH₃)]. Pyrolysis of the 23-O-thiocarbonyl derivative 3⁹ required temperatures above 180°, and heating a solution of 3 in 1,2,4-trichlorobenzene to

200° for 1 h gave a 38% yield of **4** [MS: 738, 429, 305, 433; NMR (CDCl₃) δ 5.76 (m, 3H, C₁₀H, C₁₁H, C₂₂H); 5.58 (m, 3H, C₃H, C₅H, C₂₃H)]. Treatment of **4** with p-toluenesulfonic acid monohydrate (1% in MeOH, 20 min, 18°) gave the bis-hydroxyacetyl derivative **5** [74%, MS: 624, 315, 305, 319] and further reaction with NaOMe-MeOH (0.2 molar, 60 min, 18°) gave a 61% yield of avermectin B_{1a} (**6**) identical¹⁰ with the natural product.

Reductions of certain thioesters with tri-n-butyltin hydride are generally used for the preparation of desoxy compounds from alcohols.¹¹ As the desired ivermectin (**9**) is a 23-deoxyavermectin B_{2a}, we explored the reduction of the available thiocarbonate intermediate (**3**)¹² (toluene, azobisisobutyronitrile catalyst,¹¹ 1 h reflux) and obtained desoxy compound **7** [72%, MS: 429, 307, 433], which after preparative layer chromatography was immediately treated with p-TsOH x H₂O in MeOH to give the bishydroxy acetate (**8**) [88%, MS: 626, 315, 307, 319; NMR (CDCl₃) δ 4.31 (b s, 2H, OCCH₂OH); 4.24 (b d, J = 5, OCCH₂OH)]. This gave after treatment with NaOMe-MeOH ivermectin (**9**) identical¹⁰ with material obtained by catalytic reduction⁴ of avermectin B_{1a} (**6**).

Acknowledgment. We thank Professor B. M. Trost for many stimulating discussions.

References and Notes

- 1) R. W. Burg, B. M. Miller, E. E. Baker, J. Birnbaum, S. A. Currie, R. Hartman, Y. L. Kong, R. L. Monaghan, G. Olson, I. Putter, J. B. Tunac, H. Wallick, E. O. Stapley, R. Oiwa and S. Omura, Antimicrobial Agents and Chemotherapy, **15**, 361 (1979).
- 2) T. W. Miller, L. Chalet, D. J. Cole, L. J. Cole, J. E. Flor, R. T. Goegelman, V. P. Gullo, H. Joshua, A. J. Kempf, W. R. Krellwitz, R. L. Monaghan, R. E. Ormond, K. E. Wilson, G. Albers-Schönberg and I. Putter, Antimicrobial Agents and Chemotherapy, **15**, 368 (1979).
- 3) J. R. Egerton, D. A. Ostlind, L. S. Blair, C. H. Eary, D. Suhayda, S. Cifelli, R. F. Riek and W. C. Campbell, Antimicrobial Agents and Chemotherapy, **15**, 372 (1979).
- 4) J. C. Chabala, H. Mrozik, R. L. Tolman, P. Eskola, A. Lusi, L. H. Peterson, M. F. Woods, M. H. Fisher, W. C. Campbell, J. R. Egerton and D. A. Ostlind, J. Med. Chem., **1980**, 23, 1136.
- 5) A. Wissner and C. V. Grudzinskas, J. Org. Chem., **43**, 3972 (1978).
- 6) All compounds were purified by preparative chromatography on silica gel layer plates. Their purity was established by SiO₂ TLC and HPLC on a C₁₈ µBondapak column with aqueous MeOH as mobile phase. 300 MHz ¹H NMR and mass spectra⁷ are in agreement with the assigned structures.
- 7) G. Albers-Schönberg, B. H. Arison, J. C. Chabala, A. W. Douglas, P. Eskola, M. H. Fisher, A. Lusi, H. Mrozik, J. L. Smith and R. L. Tolman, J. Am. Chem. Soc., **1981**, 103, 4216.
- 8) Satisfactory C and H analysis obtained.
- 9) H. Gerlach, T. T. Huong and W. Müller, J. C. S. Chem. Comm., **1972**, 1215.
- 10) The compounds were identical in 300 MHz ¹H NMR spectra, mass spectra, TLC (SiO₂, CH₂Cl₂-MeOH-9:1) and HPLC (Whatman ODS-2 column, MeOH-H₂O-9:1, 1.0 ml/min).
- 11) D. H. R. Barton and S. W. McCombie, J. C. S. Perkin I, **1975**, 1574.
- 12) The reduction of a thionocarbonate with tri-n-butyltin hydride was described after completion of this work as an efficient deoxygenation procedure for hindered secondary alcohols; M. H. Robins and J. S. Wilson, J. Am. Chem. Soc., **1981**, 103, 932.

(Received in USA 26 January 1982)